Target
tipiracil
16 abstracts
Abstract
Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer.Org: Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Oncology Unit 1, Department of Medical Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Phase 1 Unit, Clinical Pharmacology Center for Drug Experimentation, Pisa University Hospital, Pisa, Italy, Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padua, Italy,
Abstract
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.Org: Medical Oncology Service. Hospital G. U. Gregorio Marañón. IiSGM. Universidad Complutense, Allina Health Cancer Institute, Poitiers University Hospital and University of Poitiers, HUTCHMED Limited,
Abstract
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.Org: Oncology Unit Santa Maria delle Croci Hospital, Cardinale G Panico, Azienda Toscana Nord Ovest, University Hospital of Pisa,
Abstract
A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines.Org: National University Health Systems,
Abstract
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,
Abstract
Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.Org: Lyell McEwin Hospital, The Queen Elizabeth Hospital and University of Adelaide,
Abstract
Efficacy of trifluridine/tipiracil in 3rd or 4th line of treatment in patients with advanced or metastatic colorectal cancer: A real-world data analysis with subgroups exploration.Org: Pulmonology and Hematology Center, Department of Enviromental Health And Occupational Medicine, Wroclaw University of Science and Technology,
Abstract
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).Org: Global Biostatistical Science, Global Development,
Abstract
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.Org: Sorbonne University and Saint-Antoine Hospital, Mayo Clinic, Monash University School of Public Health and Preventive Medicine, Cardiff University School of Medicine, University of Pisa, Pisa, Italy,
Abstract
Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial.Org: Paris Cité University, Medical University of Vienna, City of Hope National Comprehensive Cancer Center, Università degli Studi della Campania Luigi Vanvitelli, Department of Gastroenterology/Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven,
Abstract
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.Org: Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Saw Swee Hock School of Public Health, National University of Singapore,
Abstract
Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study.Org: Hôpital Saint-Antoine, Paris, France, U.O. Oncologia Medica 2 Universitaria, Pisa, Italy, Lviv Cancer Center, Lviv, Ukraine, Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological), Saint-Petersburg, Russian Federation, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain,
Abstract
PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, University of Washington, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer.Org: 2nd Department of Surgery Aretaieion Hospital National and Kapodistrian University of Athens Medical School, Athens, Greece, 2nd Department of Surgery Aretaieion Hospital, Athens, Greece, 2nd Department of Suregery Aretaieion Hospital, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University, Athens, Greece, 2nd Department of Surgery, Areteion Hospital National and Kapodistrian University of Athens, Athens, Greece,
Abstract
Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study.Org: Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Changsha, China,